Adapter CAR T cell therapy for multiple synchronic immunotargeting in cancer – next generation CAR T cells
Dr Schlegel has recently joined the University of Sydney, from Tübingen, Germany, where he studied and practiced medicine, and established an independent research group in the iFIT cluster of excellence EXC 2180 at the Eberhard-Karls University.
Chimeric antigen receptor T cell therapies hold enormous promise for the treatment of a spectrum of malignancies and other indications where elimination of specific target cell types is the objective. However, life-threatening acute side effects (such as cytokine release syndrome) and chronic off-target toxicities, pose major challenges to clinical translation.
Professor Schlegel has pioneered adapter CAR T cell technology, employing a novel targeting system that has the potential to greatly improve their specificity and efficacy for the treatment of a broad range of cancers
